Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 3 of 3 citing Bopp: Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?. (0.07 sec) 

Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein …


H Wang, J Shi, Q Wang, H Li, K Cai, X Hou, T … - Cancer Immunology, Immunotherapy - Springer
Abstract Purpose A new VEGF receptor fusion protein FP3 was shown to have
promising antitumor potency better than Bevacizumab. Characterization of its
immune response is essential to the safe and effective administration in ...
Related articles - All 2 versions

Improving RPE adhesion to Bruch's membrane


FT Afshari, JW Fawcett - Eye, 2009 - nature.com
Age-related macular degeneration is the leading cause of blindness in the
developing world. Retinal pigmented epithelium (RPE) transplantation in
subretinal space, has been assessed in various animal models of age-related ...
Related articles - All 3 versions

Safety monitoring with ocular anti-vascular endothelial growth factor therapies

- prsjournal.com
AE Fung, RB Bhisitkul - British Journal of Ophthalmology, 2008 - bjo.bmj.com
Ocular anti-vascular endothelial growth factor (VEGF) therapy has brought
dramatic benefits to patients with exudative age-related macular degeneration
(AMD), and promises near-term advances in other major diseases such as ...
Related articles - All 5 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google